News for PharmaTher Holdings Ltd. (PHRRF)

KetaVaultâ„¢ to Provide Partners Unprecedented Access to PharmaTher's Extensive Regulatory, Manufacturing, and Clinical Ketamine Data, Aiming to Expedite New T

The Assigned FDA Approval Goal Date is June 4, 2025 TORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the ”œCompany” or ”œPharmaTher

PharmaTher expects to submit the MINOR AMENDMENT to the CRL by end-February 2025 and expects a new approval date for a Q2-2025 FDA approval of ketamine TORONT

TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the ”œCompany” or ”œPharmaTher”) ( PHRRF) (CSE: PHRM), a specialty pharmaceutical c

**media[505247]**

FDA provided preliminary responses to questions contained in the clarification only post-CRL meeting scheduled for December 2, 2024 PharmaTher has decided to

PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases

TORONTO, Oct. 23, 2024 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company,…

PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases

TORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company,…

PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine

TORONTO, April 18, 2024 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical…

TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical…

Psychedelics policy action took center stage this week.

The psychedelics legislative landscape continues to move forward with Hazel Park, Michigan enacting decriminalization measures for naturally-produced psychedeli...

New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:

Point Roberts, WA and Delta, BC - February 24, 2021 (Investorideas.com Newswire) Investorideas.com, a leading investor news resource on health and wellness stoc...